Ishita Drugs & Industries Limited has released its unaudited financial results for the quarter and half-year ended September 30, 2025, revealing a mixed performance amidst ongoing facility upgrades.

Financial Performance

The company reported revenue from operations of Rs. 806.81 lakhs for the quarter, contributing to a half-yearly revenue of Rs. 1499.73 lakhs. However, the net profit for the quarter saw a decline, coming in at Rs. 14.33 lakhs compared to Rs. 30.23 lakhs in the previous quarter.

The basic earnings per share (EPS) from continuing operations stood at Rs. 0.48 for the quarter.

Manufacturing Facility Upgrade

Ishita Drugs & Industries is currently undertaking a significant manufacturing facility upgradation project to comply with the Revised Schedule M regulations. The company's Board of Directors discussed the progress of this project during their meeting. Key points include:

1. Appointment of a civil contractor and commencement of construction.
2. Progress affected by higher-than-normal rainfall and an extended monsoon period.
3. Expenditure of nearly Rs. 50 lakhs incurred towards civil construction of the project.

Balance Sheet Highlights

As of September 30, 2025, the company's financial position shows:

Cash Flow and Liquidity

The cash flow statement reveals:

• Net cash generated from operating activities: Rs. 412.24 lakhs
• Net cash used in investing activities: Rs. 245.67 lakhs
• Net cash used in financing activities: Rs. 177.27 lakhs

This resulted in a net decrease of Rs. 10.70 lakhs in cash and cash equivalents for the half-year period.

The company maintains a strong liquidity position with cash and cash equivalents of Rs. 46.14 lakhs and bank balances of Rs. 426.54 lakhs as of September 30, 2025.

Ishita Drugs & Industries Limited continues to navigate through challenging market conditions while investing in its future growth through facility upgrades. The impact of these investments on the company's financial performance and market position remains to be seen in the coming quarters.

Ishita Drugs & Industries , a pharmaceutical company, has seen a significant development as Ishita Pharmaceuticals, a related party, acquired a stake in the company. The transaction, which took place on September 15, 2025, marks Ishita Pharmaceuticals' entry as a shareholder in Ishita Drugs & Industries.

Transaction Details

Ishita Pharmaceuticals acquired 25,353 shares of Ishita Drugs & Industries through an open market purchase. Each share has a face value of Rs. 10.00. This acquisition represents 0.85% of the total share capital of the target company.

Impact on Shareholding

Prior to this transaction, Ishita Pharmaceuticals held no shares in Ishita Drugs & Industries. Following the acquisition, their total holding stands at 25,353 shares, accounting for 0.85% of the voting rights in the company.

Company Capital Structure

The transaction does not affect the overall equity share capital of Ishita Drugs & Industries, which remains at Rs. 29,903,000.00. This capital is divided into 2,990,300 shares, each with a face value of Rs. 10.00.

Regulatory Compliance

In compliance with SEBI regulations, specifically Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Ishita Pharmaceuticals has made the necessary disclosures regarding this acquisition. The company filed the required documentation with the BSE Limited, where Ishita Drugs & Industries is listed under the scrip code 524400.

Market Implications

While this acquisition represents a relatively small percentage of the total shares, it signifies a new relationship between Ishita Pharmaceuticals and Ishita Drugs & Industries. As related parties, this move could potentially lead to closer cooperation or strategic alignment between the two entities in the future.

Investors and market watchers will likely monitor any further developments or transactions between these companies, as well as any potential impact on Ishita Drugs & Industries' operations or market performance.